Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Žagar Jan) .

1 - 3 / 3
First pagePrevious page1Next pageLast page
1.
Local control and survival after stereotactic body radiation therapy of early-stage lung cancer patients in Slovenia
Karmen Stanič, Jasna But-Hadžić, Jan Žagar, Martina Vrankar, 2023, original scientific article

Abstract: Background. Stereotactic body radiation therapy (SBRT) precisely and non-invasively delivers ablative radiationdose to tumors in early-stage lung cancer patients who are not candidates for surgery or refuse it. The aim of researchwas to evaluate local control, overall survival (OS), local progression free survival (LPFS), distant metastases free survival(DMFS), disease free survival (DFS) and toxicity in early-stage lung cancer patients treated with SBRT in a single tertiarycancer centre.Patients and methods. We retrospectively evaluated medical records and radiation treatment plan parametersof 228 tumors irradiated in 206 early-stage lung cancer patients between 2016 and 2021 at the Institute of OncologyLjubljana.Results. After 25 months of median follow up, 68 of 206 (33%) patients died. Median OS was 46 months (CI 36 −56),1-year, 2-year and 3-year OS were 87%, 74% and 62% and 5-year OS was 31%. A total of 45 disease progressions havebeen identified in 41 patients. Local progress only was noticed in 5 (2%) patients, systemic progress in 32 (16%) andcombined systemic and local in 4 (2%) patients. Local control rate (LCR) at 1 year was 98%, at 2 and 3 years 96%and 95% at 5 years. The 1-, 2- and 3-year LPFS were 98%, 96% and 94%, respectively and 5-year LPFS was 82%. One,2-, 3- and 5-year DFS w ere 89%, 81%, 72% and 49%, respectively. Among 28 toxicities recorded only one was Grade4 (pneumonitis), all others were Grade 1 or 2. No differences in LCR, LPFS, DFS were found in univariate analysis com-paring patient, tumor, and treatment characteristics. For OS the only statistically significant difference was found inpatients with more than 3 comorbidities compared to those with less comorbidities.Conclusions. Early lung cancer treated with SBRT at single tertiary cancer centre showed that LCR, LPFS, DFS, DMFSand OS were comparable to published studies. Patients with many comorbidities had significantly worse overallsurvival compared to those with less comorbidities. No other significant differences by patient, tumor, or treatmentcharacteristics were found for DMFS, LPFS, and DFS. Toxicity data confirmed that treatment was well tolerated.
Keywords: stereotactic body radiotherapy, early-stage lung cancer, lung cancer
Published in DiRROS: 25.07.2024; Views: 242; Downloads: 116
.pdf Full text (326,62 KB)
This document has many files! More...

2.
Stresni zlomi medenice po zdravljenju z obsevanjem : pregled literature
Jan Žagar, Barbara Šegedin, 2023, review article

Abstract: Stresni zlomi medenice po obsevanju so že dolgo znana posledica obsevanja tumorjev v področju medenice. Čeprav so zlasti v področju sakruma relativno pogost pojav, je njihova diagnostika zaradi nespecifičnosti simptomov težavna. V tem preglednem članku smo pregledali literaturo, ki zajema etiologijo, incidenco, dejavnike tveganja, simptome in diagnostiko ter zdravljenje in preprečevanje stresnih zlomov medenice po obsevanju. Na podlagi pridobljenih podatkov smo poskušali strniti in predstaviti najdene ugotovitve z navedenih področij, ki bi nam bile lahko v pomoč v vsakodnevni radioterapevtski klinični praksi, saj standardiziranih priporočil na tem področju nismo našli.
Keywords: stresni zlomi medenice, obsevanje, incidenca
Published in DiRROS: 27.07.2023; Views: 802; Downloads: 164
.pdf Full text (231,02 KB)

3.
Klinični primer multimodalnega zdravljenja bolnika z nedrobnoceličnim rakom pljuč stadija III
Staša Jelerčič, Jan Žagar, 2023, published scientific conference contribution

Abstract: Nedrobnocelični rak pljuč stadija III predstavlja izjemno heterogeno skupino bolezni, kjer so podobno heterogene tudi možnosti zdravljenja; od primarne operacije ter dopolnilne kemoterapije, do predoperativne kemoradioterapije in nato operacije ter nenazadnje definitivne kemoradioterapije in imunoterapije pri inoperabilnih bolnikih. O najustreznejši strategiji zdravljenja se za vsakega pacienta odločamo individualno na multidisciplinarnih konzilijih.
Keywords: pljučni rak, onkološko zdravljenje, bolniki
Published in DiRROS: 12.05.2023; Views: 804; Downloads: 162
.pdf Full text (84,19 KB)

Search done in 0.12 sec.
Back to top